S
ickle cell disease is associated with acute painful episodes and chronic intractable pain. Endothelin-1, a known pain inducer, is elevated in the blood plasma of both sickle cell patients and mouse models of sickle cell disease. We show here that the levels of endothelin-1 and its endothelin type A receptor are increased in the dorsal root ganglia of a mouse model of sickle cell disease. Pharmacologic inhibition or neuron-specific knockdown of endothelin type A receptors in primary sensory neurons of dorsal root ganglia alleviated basal and post-hypoxia evoked pain hypersensitivities in sickle cell mice. Mechanistically, endothelin type A receptors contribute to sickle cell disease-associated pain likely through the activation of NF-κB-induced Nav1.8 channel upregulation in primary sensory neurons of sickle cell mice. Our findings suggest that endothelin type A receptor is a potential target for the management of sickle cell disease-associated pain, although this expectation needs to be further verified in clinical settings.
Endothelin type A receptors mediate pain in a mouse model of sickle cell disease Introduction
Sickle cell disease (SCD) results from an amino acid substitution in the β globin chain of the oxygen carrying molecule, hemoglobin. 1 Approximately 100,000 Americans currently suffer from SCD, and over 80,000 SCD related hospitalizations occur annually resulting in over 450 million dollars in healthcare costs. 2 Much of these healthcare costs and hospitalizations stem from acute vaso-occlusive episodes in which patients often report extreme pain. 3 Pain is a hallmark of SCD and correlates with morbidity and disease severity. 4 In addition to acute painful episodes, some SCD patients report persistent/chronic pain. 5 Treatment for SCDassociated pain includes pain medications such as opioids, but pain relief may remain inadequate for many SCD patients. Additionally, repeated and/or prolonged administration of these drugs has potential side effects. 6 Understanding the causes of pain in SCD may bring forward new and more efficient therapeutic strategies for the management of SCD pain.
Endothelin-1 (ET-1) is a 21 amino acid peptide released from endothelial cells, immune cells, and neurons. 7 ET-1 binds to endothelin type A (ET A ) and endothelin type B (ET B ) G-protein coupled receptors. 7 Classically, ET-1 acts as a vaso-constrictor, but recent studies have shown that ET-1 can also induce pain in humans and rodents. 8, 9 In the dorsal root ganglia (DRG), ET A receptors are expressed predominantly in the primary sensory neurons, while ET B receptors are detected in glial cells. 10 Blocking ET A receptors attenuates ET-1-induced nerve fiber activation and pain behavior in rodents. 7, 11, 12 ET-1-induced activation of the ET A receptor has been found to increase intracellular calcium release, potentiate transient receptor potential vanilloid 1 current, and alter the functioning of tetrodotoxin-resistant (TTX-R) sodium channels in DRG neurons, 8 but detailed mechanisms of how ET-1 induces pain are not fully understood.
In SCD patients, blood plasma ET-1 levels are elevated at a basal level and increase further during an acute vasoocclusive crisis. 13, 14 Elevated ET-1 and its subsequent activation of ET A receptors have been demonstrated to contribute to SCD pathology, including renal injury 15 and pulmonary hypertension. 16 The level of ET-1 mRNA is also increased in the DRG of SCD mice. 17 However, whether and how this elevated ET-1 in SCD DRG contributes to SCD-associated pain remains elusive. Given that ET A receptor antagonists have been used in phase II/III clinical trials for cancer treatment 18, 19 and SCD-related pulmonary hypertension, 16 identifying the role of ET-1 and its ET A receptors in SCD-associated pain may provide a new avenue for treatment of SCD-associated pain in patients.
Humanized mouse models of SCD display persistent pain hypersensitivity that can worsen with exposure to hypoxia. 17, 20, 21 In the present study, using the humanized Townes (HbSS) and Berkeley (BerkSS) mouse models of SCD, we first examined whether local pharmacologic inhibition or conditional knockout of ET A receptors in DRG neurons affected pain hypersensitivity in SCD mice. We then examined whether SCD mice expressed elevated levels of ET-1 and ET A receptors in DRG neurons. Finally, we unveiled a possible molecular mechanism by which DRG ET A receptors mediate SCD pain through the activation of NF-κB and subsequent increase of Nav1.8 expression in the DRG.
Methods

Animals
All procedures used in this study have been approved by the Rutgers New Jersey Medical School Animal Care and Use Committee and adhere to the ethical guidelines of the National Institutes of Health and the International Association for the Study of Pain. All experiments were designed to minimize animal suffering and the number of animals used, and were conducted in a blind manner. Detailed animal information can be found in Online Supplementary Methods.
Behavioral analysis
Mechanical testing, thermal testing, and cold testing were conducted on the same day with at least 1 hour rest periods between tests as described. 22 The conditioned place-preference (CPP) test was carried out as described 22 and in the Online Supplementary Methods.
Hypoxia/Reoxygenation
Hypoxia/reoxygenation exposure for the induction of vasoocclusion was conducted in the same manner as previously described. 20 The detailed procedures can be found in the Online Supplementary Methods.
Genetic Knockdown and Bone Marrow Transplantation
Chimeric mouse generation was completed using a previously described protocol, which showed the development of the sickle cell phenotype in BerkSS bone marrow-recipient mice beginning at 2 months after transplantation. 23 The detailed procedures can be found in the Online Supplementary Methods.
Isoelectric focusing, cell culture, immunofluorescence, Western blotting, qRT-PCR, ChIP assay, luciferase assay, electrophysiological recording, and statistical analysis methods can be found in the Online Supplementary Methods.
Results
Pain hypersensitivity in SCD mouse models
We first characterized basal pain behaviors in our colony of Townes humanized SCD mice. HbSS and HbAA mice (as a control) aged 4-6 months were used. Like male BerkSS mice (Online Supplementary Figure S2A , B), male HbSS mice displayed significant bilateral increases in basal paw withdrawal frequencies (PWF) in response to 0.16 g and 0.4 g von Frey filaments (Figure 1 A, B) , and reductions in paw withdrawal latencies (PWL) to both thermal and cold stimuli when compared to their HbAA littermates (Figure 1 C, D) . Similar pain hypersensitivities were seen in female HbSS mice (Online Supplementary  Figure S3 A-D) .
We then examined whether pain hypersensitivities stemmed from an increase in DRG neuronal excitability in HbSS mice. Compared to HbAA mice, the medium and small DRG neurons of HbSS mice showed increases of 9.85 mV and 8.24 mV, respectively, in the resting membrane potentials ( Figure 2A ) and decreases of 36% and 52%, respectively, in the current thresholds for action potential generation ( Figure 2B ). The number of action potentials evoked by a stimulation of ≥ 200 pA in medium and small neurons was significantly higher in HbSS mice ( Figure 2C , D), although both mice displayed similar membrane input resistances and other action potential parameters, (Online Supplementary Table S1 ). In addition, a larger percentage of small and medium HbSS DRG neurons exhibited spontaneous activity compared to HbAA DRG neurons (Figure 2 E, F) . The frequency of spontaneous action potential generation was also higher in HbSS small and medium DRG neurons compared to HbAA neurons (Figure 2 G) . These indicators of heightened excitability were not seen in large DRG neurons (Figure 2 A-G).
Effect of DRG ET A receptor inhibition on SCD pain
To address the role of DRG ET A receptors in SCD-associated pain, we subcutaneously (s.c.) injected ABT-627, a selective and specific ET A receptor antagonist, 24 into the plantar side of the left hindpaw. Single administration of 5 nmol ABT-627, 2 hours before behavioral testing under normoxic conditions, led to the attenuation of ipsilateral mechanical (Figure 3A Exposure to hypoxia/reoxygenation in SCD mice has been implicated as a method of inducing vaso-occlusion and mimicking acute painful episodes in SCD patients. 20 We further performed behavior analyses following hypoxia/reoxygenation exposure in SCD mice. Male HbSS mice exhibited similar responses to the 0.4 g von Frey filament ( Figure 3B ), thermal ( Figure 3C ), and cold ( Figure 3D ) stimuli before and after hypoxia/reoxygenation. However, after hypoxia/reoxygenation, bilateral PWF to the 0.16 g von Frey filament increased by 20% in male HbSS mice compared to basal values ( Figure 3A) . ABT-627 administered to the unilateral hind paw immediately after hypoxMouse model of sickle cell disease haematologica | 2018; 103 (7)ia exposure, led to the attenuation of ipsilateral mechanical, thermal, and cold pain hypersensitivities in male HbSS mice ( Figure Spontaneous ongoing pain in HbSS mice using a CPP paradigm was also examined. HbSS mice, but not HbAA mice, given vehicle once a day for 4 days prior to and during CPP testing (Online Supplementary Figure S1 ), spent significantly more time in the lidocaine-paired chamber after conditioning compared to their pre-test time (Figure 3 
Effect of knockdown of DRG ET A receptors on SCD pain
The effects of ABT-627 hindpaw administration described above suggest the role of peripheral ET A receptors in SCD-associated pain; however, ABT-627 lacks celltype specificity and may also have off-target effects. As a complementary approach, we generated a DRG neuronspecific ET A receptor knockout mouse by crossing an ET A flox/flox mouse with an Advillin cre/+ mouse in which Crerecombinase is expressed only in Advillin-positive neurons exclusive to the DRG and trigeminal ganglia. DRGspecific knockdown of ET A receptors was validated using Western blotting and immunostaining (Online Supplementary Figure S8 A, B). Two months after bone marrow transplantation, donor hemoglobin expression in the recipient mice was confirmed using isoelectric focusing (Online Supplementary Figure S8 
Increased ET-1 and ET A receptor expression in SCD DRG
Our behavioral observations indicate the significance of DRG ET A receptors in pain hypersensitivity in HbSS mice. We next examined the expression of the ET A receptor and Figure S9) . About 36% of pre-pro ET-1-labeled neurons are positive for CGRP, 56% for IB4, and 7% for NF200 ( Figure 5C ). The percentage of neurons expressing ET A receptors or pre-pro ET-1 within the DRG of HbSS mice was 45% and 32%, respectively, higher than those in the HbAA DRG ( Figure 5 D, E) . Unexpectedly, there was no significant difference in hindpaw expression of ET-1 or ET A receptors between HbAA and HbSS mice ( Figure 5F ).
Effect of ET A receptor inhibition on Nav1.8 expression and channel activity in SCD DRG
Previous studies have shown that ET-1 can alter the activity of TTX-R sodium channels in rat DRG neurons. Nav1.8, a TTX-R sodium channel in DRG, participates in chronic inflammatory pain genesis. 27 We first determined if Nav1.8 expression differed between HbAA and HbSS DRG. The levels of Scn10a mRNA (encoding Nav1.8) and Scn11a mRNA (encoding Nav1.9, another TTX-R sodium channel) were elevated in HbSS DRG ( Figure 6A ). The amount of Nav1.8 protein and the percentage of Nav1.8-positive neurons were also increased in HbSS DRG (Fig. 6  B, C) . Four days of hindpaw ABT-627 administration abolished the increase in Nav1.8 protein in HbSS DRG (Figure  6 B), indicating that increased Nav1.8 requires ET A receptor activation in SCD (HbSS) DRG.
Furthermore, we analyzed Nav1.8 activity in HbSS DRG neurons. Whole cell voltage-clamp recordings were performed in freshly disassociated small DRG neurons since Nav1.8 is expressed predominantly in small DRG neurons. 28 Neurons were held at -60 mV, given a depolarizing step at 50 ms from -55 mV to +40 mV with a 5 mV increment ( Figure 7A ). Under this protocol with the presence of 500 nM TTX, Nav1.9 current was inhibited to keep the Nav1.8 current integrated.
29 Nav1.8 current density from the HbSS DRG neurons significantly increased compared to HbAA DRG neurons ( Figure 7A, B) . Bilateral subcutaneous ABT-627 administered daily over 4 days prior to DRG collection produced a larger reduction in Nav1.8 current density in HbSS DRG compared to HbAA DRG ( Figure 7A , B). When tested at -15 mV, ABT-627 reduced Nav1.8 current by approximately 300 pA in HbSS DRG neurons, with no change in the HbAA DRG neurons
Mouse model of sickle cell disease haematologica | 2018; 103 (7) 1127 ( Figure 7C ). These data further indicate that the increase in Nav1.8 current from HbSS DRG neurons is ET A receptordependent. We also examined the gating properties of Nav1.8 in HbSS DRG neurons. HbSS DRG neurons showed a hyperpolarizing potential shift compared to HbAA DRG neurons under the conditions of either activation or inactivation of Nav1.8 ( Figure 7 D, E) . The halfmaximal activation voltage (V1/2) was -20.35 ± 1.16 mV in the HbAA mice and -24.79 ± 0.93 mV in the HbSS mice ( Figure 7D ), whereas the half-maximal inactivation voltage (V1/2) was -37.56 ± 1.32 mV in the HbAA mice and -45.80 ± 1.80 mV in the HbSS mice ( Figure 7E ). In vivo administration of ABT-627 as described above did not lead to changes in the gating properties of Nav1.8 in HbAA or HbSS mice. HbSS DRG neurons likely display ET A receptor-independent changes in the gating properties of Nav1.8 channels.
NF-κ B-triggered Nav1.8 expression in HbSS DRG neurons
How does ET A receptor activation mediate an increase in Nav1.8 expression and activity in SCD (HbSS) DRG neurons? The transcription factor, NF-κB, may be upstream of Nav1.8 upregulation in DRG neurons and is
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haematologica | 2018; 103(7) activated by ET-1. 30, 31 To confirm this relationship among ET-1, ET A receptors, and Nav1.8 channels in DRG neurons, we cultured HbAA DRG neurons in the presence of ET-1 peptide. ET-1 stimulation of HbAA DRG neurons for 24 hours resulted in increases in the levels of Nav1.8 protein ( Figure 8A ) and phosphorylated p65 protein (an indicator of NF-κB activation 32 ), a NF-κB subunit ( Figure 8B ). Co-incubation with ABT-627 or pyrrolidine dithiocarbamate (PDTC), an NF-κB-specific inhibitor, prevented these increases ( Figure 8A and 8B) . Furthermore, we examined the expression of phosphorylated p65 in in vivo mice injected intraperitoneally (i.p) with vehicle or ABT-627 once daily for 4 days. Phosphorylated p65 levels in HbSS DRG significantly increased after vehicle injection, but did not significantly change after ABT-627 administration compared to that in the HbAA mice after vehicle injection ( Figure 8C ). Total p65 protein levels did not significantly differ among treatment groups ( Figure 8C ). These findings indicate that NF-κB activation and Nav1.8 upregulation in HbSS DRG are ET A receptor-dependent and may be involved in SCD-associated pain. This conclusion is further supported by our behavioral observations that single i.p administration of PDTC, a specific inhibitor of NF-κB activation, or A-803467, a specific antagonist of Nav1. 8, 33 alleviated mechanical allodynia and/or thermal hyperalgesia in HbSS mice, without affecting the basal responses of HbAA mice ( Figure 8D ; Online Supplementary Figure S10) .
We then examined whether activated NF-κB is directly linked to increased Nav1.8 expression in HbSS DRG. Using ChIP analyses, a fragment within the Scn10a promoter was amplified from a complex immunoprecipitated with an anti-p65 antibody (Figure 8E ), indicating the binding of p65 to the Scn10a gene promoter in the DRG. This binding activity increased in the HbSS DRG compared to HbAA DRG, as shown by a 7-fold increase in band density ( Figure 8E ). To examine whether NF-κB activation directly regulates Scn10a transcriptional activity, we performed a dual luciferase assay using a mouse neuronal cell line (CAD cells) 34 transfected with a luciferase reporter vector containing the Scn10a gene promoter. Since phorbol 12-myristate 13-acetate (PMA) can activate NF-κB through protein kinase C (PKC) activation, 35 we applied
Mouse model of sickle cell disease haematologica | 2018; 103(7) Figure 8F ). Co-administration of PDTC or bisindolylmaleimide I (BIM), a PKC inhibitor, prevented this increase ( Figure 8F ). BIM or PDTC alone did not affect basal luciferase activity ( Figure  8F ). These results indicate that the increased Scn10a gene activity is a specific response to PKC/NF-κB activation. Single-cell RT-PCR analysis revealed that 40% of individual small DRG neurons co-expressed Scn10a mRNA, Ednra mRNA, and Rela mRNA (encoding p65) ( Figure 8G ). Taken together, our findings suggest the participation of NF-κB in ET A receptor-dependent Nav1.8 upregulation in HbSS DRG neurons (Online Supplementary Figure S11) .
Discussion
Pain is a major symptom reported by SCD patients. Currently, painkillers such as opioids are prescribed for SCD pain management but repeated and/or prolonged administration of these drugs has limited analgesic efficacy and the potential to produce side effects. 6 Identifying novel and specific targets for pain management is essential for improving SCD patient care. We showed here that the expression of ET-1 and its ET A receptor increases in the DRG of SCD mice. Sensory neuron-specific knockdown or local inhibition of DRG ET A receptors alleviated basal and post-hypoxia mechanical allodynia and thermal/cold hyperalgesia in SCD mice. Although the exact mechanism 
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underlying these effects requires further validation in SCD mouse models, our study suggests that ET A receptors are key players in SCD-associated pain. The present study used two humanized mouse models of SCD, the Berkeley and Townes, to analyze SCD-associated pain. Although pain-like behaviors in SCD mouse models may not exactly mimic pain in SCD patients due to several confounding environmental and emotional variables, analyzing pain hypersensitivity in SCD murine models is a productive tool for identifying the underlying mechanisms of SCD-associated pain. These mice displayed significant mechanical allodynia, thermal/cold hyperalgesia, and spontaneous ongoing pain consistent with previous reports. 36 Using age-matched male and female HbSS and HbAA littermates, we found no significant sex-based differences in basal or post-hypoxia evoked pain hypersensitivity or ABT-627 efficacy. This aligns with clinical reports that found no significant differences in self-reported pain experiences between maleand female SCD patients. 37, 38 Interestingly, Townes HbSS mice did not display a similar degree of pain exacerbation following hypoxia/reoxygenation compared to the BerkSS mice. This may be related to the presence of a human β-globin locus control region (LCR) that leads to hemoglobin switching similar to humans in the Townes HbSS mice, although both models express human globins. In the Townes model, relative g-globin expression (g/g+βS) at birth is between 30% to 50%, then β-globin expression dominates at 1 month of age. 39 In contrast, the Berkeley model exhibits a complete g-globin to β-globin switch in utero leading to greater prenatal death and low birth rates. Given that higher g-globin expression is associated with diminished SCD symptoms, 40 the early expression of βs-globin in BerkSS mice may cause more severe symptoms of SCD, which could explain their significant pain exacerbation following hypoxia/reoxygenation.
An increase in ET A receptor expression may be attributed to the elevated ET-1 in the DRG neurons of HbSS mice. The levels of ET-1 mRNA, ET-1 protein, and ET A receptor protein increased in HbSS DRG. Consistent with previous studies, 10, 25 ET-1 and ET A receptors are predominantly expressed in DRG neurons, although ET-1 expression in immune cells found in HbSS DRG cannot be ruled out. 41 Elevated ET-1 could trigger increased ET A receptor expression in DRG possibly through increased receptor cycling to the membrane and/or enhanced transcription or translation. 42, 43 Since we found no significant changes in ET A receptor mRNA in HbSS DRG, it would be expected that, under constantly elevated ET-1 conditions, ET-1/ET A receptor cycling coupled with ET-1-triggered activation of intracellular signals enhances ET A receptor translation through unknown mechanisms in HbSS DRG. The mechanism of ET A receptor upregulation in HbSS DRG remains to be further investigated.
ET A receptors are required for increased Nav1.8 expression in HbSS DRG, since ET A receptor inhibition completely blocked increases in Nav1.8 protein and current in HbSS DRG. However, whether the participation of DRG ET A receptors in the pain hypersensitivity of HbSS mice is mediated by DRG Nav1.8 upregulation in HbSS mice requires further investigation as the present data showed only an association between activation of the ET A receptors and upregulation of Nav1.8 in the DRG of HbSS mice. Interestingly, ET A receptor inhibition did not alleviate the hyperpolarizing shift in the gating properties of Nav1.8 channels in HbSS DRG. Previous studies reported that phosphorylation of Nav1.8 channels by protein kinase A (PKA), but not PKC, could affect the channel's gating properties. 44, 45 The altered gating of Nav1.8 channels in the HbSS DRG is likely the result of activation of PKA by an ET A receptor-independent signaling mechanism. It is worth noting that the leftward shift of 4.44 mV in the HbSS DRG would only result in a modest increase in sodium current. 26 Given that ABT-627 fully attenuated the increase in Nav1.8 current in the HbSS DRG, an ET A -receptor independent mechanism of Nav1.8 channel 
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phosphorylation may not be a significant contributor to Nav1.8-mediated neuronal excitability and behavioral pain hypersensitivity. Additionally, we observed that the resting membrane potential of HbSS DRG neurons was elevated. This suggests a possible decrease in potassium channel expression or function. ET-1 has been shown to depress delayed rectifier potassium currents in rat DRG neurons. 46 This depression of potassium currents may be involved in increased excitability of SCD neurons and the pain hypersensitivity of SCD mice found in this study. Thus, it is of interest to further examine whether the expression of other ion channels including delayed rectifier potassium channels differs between HbAA and HbSS DRG neurons and whether these differences are ET A receptor-dependent.
NF-κB may be a key modulator of ET A receptor-dependent Nav1.8 upregulation in HbSS DRG. NF-κB is expressed in small and medium neurons of the DRG. 47 Under inflammatory conditions, PKCε activation has been linked to Nav1.8 upregulation in DRG neurons 48 and NF-κB activation. 49 A recent study also reported that chemokine ligand 2 can induce NF-κB activation via PKC and lead to Nav1.8 upregulation in DRG neurons. 30 Since ET A receptor activation leads to the downstream activa-
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tion of PKCε and PKCd, 50 it is likely that ET A receptors contribute to increased Nav1.8 expression through NF-κB activation in HbSS DRG. NF-κB activation was indeed enhanced in ET-1-stimulated cultured DRG neurons and in vivo HbSS DRG, and this enhanced activation was ET A receptor-dependent. NF-κB binding to the Scn10a (Nav1.8) promoter region increased in HbSS DRG. Additionally, PKC-induced NF-κB activation led to increased Scn10a promoter activity in mouse neuronal cells. These findings suggest that the Nav1.8 upregulation found in HbSS DRG is the result of ET-1/ET A receptorinduced NF-κB activation. However, the involvement of Mouse model of sickle cell disease haematologica | 2018; 103 (7) 1133 
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other transcription factors or molecules in ET-1/ET A receptor-mediated Nav1.8 upregulation in HbSS DRG could not be excluded.
In conclusion, this study provides evidence for one possible mechanism by which ET-1/ET A receptors contribute to SCD-associated pain likely through the NF-κB-triggered upregulation of Nav1.8 in primary sensory neurons. We identified the ability of ABT-627, an ET A receptorspecific antagonist, 24 to alleviate basal and post-hypoxia evoked pain hypersensitivity in SCD mice. At the dosages used, ABT-627 produced pain relief that persisted for the entire testing period (at least 7 hours) with no noticeable side effects. Given that ABT-627 and similar ET A receptor antagonists have been used in phase II/III clinical trials for cancer treatment 18, 19 and are beneficial for SCD-related pulmonary hypertension, 16 targeting DRG ET A receptors may have potential therapeutic value for SCD-associated pain management. 
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